Evidence map›Paper›PMID 28122530›Full record

ArticleBMC public health2017

VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation.

Yu Xie, Xiaodong Tan, Haiyan Shao, Qing Liu, Jiyu Tou, Yuling Zhang, Qiong Luo, Qunying Xiang

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Cervical cancer screening aided by artificial intelligence, China.Bulletin of the World Health Organization · 2023
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yu XieSchool of Public Health, Wuhan University, Hubei, China.
Xiaodong TanSchool of Public Health, Wuhan University, Hubei, China. 00300469@whu.edu.cn.
Haiyan ShaoSchool of Public Health, Wuhan University, Hubei, China.
Qing LiuSchool of Public Health, Wuhan University, Hubei, China.
Jiyu TouInstitute of Cancer Prevention and Control, Hubei, China.
Yuling ZhangInstitute of Cancer Prevention and Control, Hubei, China.
Qiong LuoMaternal and Child Health Care Hospital, Wufeng, China.
Qunying XiangMaternal and Child Health Care Hospital, Wufeng, China.
Wuhan University · CNHubei Provincial Center for Disease Control and Prevention · CNYunnan Maternal and Child Health · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundScreening is the main preventive method for cervical cancer in developing countries, but each type of screening has advantages and disadvantages. To investigate the most suitable method for low-income areas in China, we conducted a health economic analysis comparing three methods: visual inspection with acetic acid and Lugol's iodine (VIA/VILI), ThinPrep cytology test (TCT), and human papillomavirus (HPV) test.

methodsWe recruited 3086 women aged 35-65 years using cluster random sampling. Each participant was randomly assigned to one of three cervical cancer screening groups: VIA/VILI, TCT, or HPV test. In order to calculate the number of disability-adjusted life years (DALYs) averted by each screening method, we used Markov models to estimate the natural development of cervical cancer over a 15-year period to estimate the age of onset and duration of each disease stage. The cost-effectiveness ratios (CERs), net present values (NPVs), benefit-cost ratios (BCRs), and cost-utility ratios (CURs) were used as outcomes in the health economic analysis.

resultsThe positive detection rate in the VIA/VILI group was 1.39%, which was 4.6 and 2.0 times higher than the rates in the TCT and HPV test groups, respectively. The positive predictive value of VIA/VILI (10.53%) was highest while the rate of referral for colposcopy was lowest for those in the HPV + TCT group (0.60%). VIA/VILI performed the best in terms of health economic evaluation results, as the cost of per positive case detected was 8467.9 RMB, which was 24503.0 RMB lower than that for TCT and 5755.9 RMB lower than that for the HPV test. In addition, the NPV and BCR values were 258011.5 RMB and 3.18 (the highest), and the CUR was 2341.8 RMB (the lowest). The TCT performed the worst, since its NPV was <0 and the BCR was <1, indicative of being poorly cost-beneficial.

conclusionsWith the best economic evaluation results and requiring minimum medical resources, VIA/VILI is recommended for cervical cancer screening in poverty-stricken areas in China with high incidence of cervical cancer and lack of medical resources.

Indexed as

Cost-Benefit AnalysisAcetic AcidAdultAgedChinaEarly Detection of CancerFemaleHumansIncidenceIodidesMass ScreeningMiddle AgedPapillomaviridaePovertyQuality-Adjusted Life YearsUterine Cervical NeoplasmsAcetic AcidIodidesLugol's solutionCervical cancerHealth economic evaluationMarkov modelScreening

Identifiers

PMID28122530
PMCPMC5264329
OpenAlexW2581142080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.